Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers

Int J Mol Sci. 2023 Aug 24;24(17):13179. doi: 10.3390/ijms241713179.

Abstract

The term "cancer stem cell" (CSC) refers to a cancer cell with the following features: clonogenic ability, the expression of stem cell markers, differentiation into cells of different lineages, growth in nonadhesive spheroids, and the in vivo ability to generate serially transplantable tumors that reflect the heterogeneity of primary cancers (tumorigenicity). According to this model, CSCs may arise from normal stem cells, progenitor cells, and/or differentiated cells because of striking genetic/epigenetic mutations or from the fusion of tissue-specific stem cells with circulating bone marrow stem cells (BMSCs). CSCs use signaling pathways similar to those controlling cell fate during early embryogenesis (Notch, Wnt, Hedgehog, bone morphogenetic proteins (BMPs), fibroblast growth factors, leukemia inhibitory factor, and transforming growth factor-β). Recent studies identified a subpopulation of CD133+/CD24+ cells from ccRCC specimens that displayed self-renewal ability and clonogenic multipotency. The development of agents targeting CSC signaling-specific pathways and not only surface proteins may ultimately become of utmost importance for patients with RCC.

Keywords: CD133; cancer stem cell; markers; renal cell carcinoma; treatment.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Carcinoma, Renal Cell*
  • Cell Differentiation
  • Humans
  • Kidney Neoplasms*
  • Neoplastic Stem Cells

Substances

  • Biomarkers

Grants and funding

This research received no external funding.